Carcinosarcoma of the Corpus Uteri

Carcinosarcoma of the corpus uteri is a rare, very aggressive cancer of the womb (uterus). It has two parts inside the same tumor: a carcinoma part (from the inner lining called endometrium) and a sarcoma part (that looks like muscle or other supporting tissues). Today, experts consider it mainly an epithelial cancer (a type of endometrial carcinoma) that has changed its look and behavior to appear partly like a sarcoma. It grows fast and often spreads outside the uterus. Because of that, doctors treat it like a high-risk endometrial cancer using surgery and combination chemotherapy, and sometimes radiation or immunotherapy depending on stage and tumor biology. ecancer+2cancer.gov+2

Carcinosarcoma of the uterus is a rare and aggressive uterine cancer that contains two parts in the same tumor: a carcinoma (epithelial) part and a sarcoma (connective-tissue) part. Modern pathology treats it mainly like a very high-grade endometrial carcinoma because the carcinoma part drives how the disease behaves and spreads. Doctors stage it using the 2023 FIGO endometrial cancer system, not a sarcoma system. MDPI+2PMC+2

It usually affects post-menopausal women and often presents with abnormal or post-menopausal bleeding. Imaging (ultrasound/MRI) and tissue biopsy confirm the diagnosis; molecular profiling (e.g., MMR/MSI, p53, POLE) is encouraged because it can guide adjuvant treatment choices. PMC+1

---

Other names

This tumor has been called by several names in the past. You may see these in older reports:

• Malignant mixed Müllerian tumor (MMMT)

• Malignant mixed mesodermal tumor

• Uterine carcinosarcoma (UCS)

All these names refer to the same disease. Modern texts prefer “uterine carcinosarcoma.” SAGE Journals+1

---

Types

Doctors may describe types in a few simple ways:

1. By the sarcoma component

• Homologous type: the sarcoma part looks like tissues normally found in the uterus (for example, smooth muscle).

• Heterologous type: the sarcoma part looks like tissues not normally in the uterus (for example, cartilage or bone).
  These details come from the pathologist’s microscope report and can relate to behavior and treatment planning. ecancer

2. By stage (how far it has spread)

• Early (confined to uterus) vs advanced (beyond uterus or to distant sites). Staging guides surgery and the need for chemo and radiation. cancer.gov

3. By molecular features (tumor biology)
   Many tumors have TP53 (p53) abnormalities and other endometrial cancer-type mutations (for example, PIK3CA or PTEN). Some show mismatch-repair deficiency (MMRd) or MSI-H, which can guide immunotherapy. HER2 can be amplified in a subset, which sometimes changes systemic therapy choices. Pathology labs test for these on biopsy or surgical tissue. Annals of Oncology+1

---

Causes

Researchers do not know one single cause, but several factors raise risk. Think of these as “reasons your risk goes up,” not guarantees that cancer will happen.

1. Older age: most patients are postmenopausal. Risk rises with age. PMC

2. Obesity: higher body fat raises estrogen levels, which can drive endometrial cancers, including carcinosarcoma. PMC

3. Unopposed estrogen exposure: long estrogen exposure without progesterone balance increases endometrial cancer risk. cancer.gov

4. Tamoxifen use: past or prolonged tamoxifen for breast cancer can increase risk of aggressive endometrial tumors, including carcinosarcoma. ejgo.net+1

5. Prior pelvic radiation: radiation to the pelvis in the past can raise risk of uterine sarcomas and aggressive endometrial tumors. cancer.gov

6. Diabetes: metabolic issues often travel with obesity and can increase endometrial cancer risk overall. cancer.gov

7. High blood pressure: often clusters with obesity and diabetes; linked with higher endometrial cancer risk. cancer.gov

8. Early first period / late menopause: more lifetime periods means more estrogen exposure. cancer.gov

9. Never having been pregnant (nulliparity): fewer breaks from estrogen cycles may increase risk. cancer.gov

10. Family history of endometrial or colon cancer: shared genetic and lifestyle risks can play a role. cancer.gov

11. Lynch syndrome (MMR gene mutation): increases risk of several cancers, including some endometrial cancers; MMR testing guides therapy. Annals of Oncology

12. Long-term hormone therapy without progesterone: continuous estrogen alone can raise risk. cancer.gov

13. Polycystic ovary syndrome (PCOS): long-term anovulation raises unopposed estrogen exposure. cancer.gov

14. Older age at first birth or few births: related to lifetime estrogen exposure. cancer.gov

15. Certain racial disparities: Black women have higher rates of aggressive endometrial subtypes, including carcinosarcoma; causes are complex (biology, access, and social factors). ScienceDirect

16. Smoking cessation weight gain (indirect): obesity after quitting can raise risk via hormone pathways (smoking itself is not protective and is harmful overall). cancer.gov

17. Atypical endometrial hyperplasia history: a precancer condition that can evolve into high-risk cancers. cancer.gov

18. Long gaps without periods (chronic anovulation): increases unopposed estrogen time. cancer.gov

19. Genetic changes in tumor (like TP53): not a lifestyle cause but reflects the biology that drives this cancer’s aggressive behavior. Annals of Oncology

20. General factors that weaken overall health (poor diet, inactivity): these cluster with obesity and diabetes, raising endometrial cancer risk overall. cancer.gov

---

Symptoms

Symptoms often look like other uterine problems. Any new bleeding after menopause should be checked quickly.

1. Postmenopausal vaginal bleeding: the most common warning sign. Even light spotting matters. cancer.gov

2. Irregular bleeding before menopause: heavier or longer periods than usual. cancer.gov

3. Watery or blood-stained vaginal discharge: may have a foul smell. cancer.gov

4. Pelvic pain or pressure: a feeling of fullness or cramping low in the belly. cancer.gov

5. A growing pelvic or abdominal mass: sometimes felt on exam. cancer.gov

6. Pain during sex: due to a bulky uterine mass or tenderness. cancer.gov

7. Pain with urination or bowel movements: tumor pressure on the bladder or rectum. cancer.gov

8. Frequent urination: pressure effect on the bladder. cancer.gov

9. Constipation: pressure on the bowel. cancer.gov

10. Unintended weight loss: sign of advanced disease. cancer.gov

11. Tiredness and low energy: often from anemia due to bleeding. cancer.gov

12. Lower back pain: referred pain from the pelvis. cancer.gov

13. Swelling of the legs: if lymph nodes are blocked. cancer.gov

14. Shortness of breath: if severe anemia or lung spread in advanced cases. cancer.gov

15. Loss of appetite or early fullness: general cancer-related symptoms. cancer.gov

---

Diagnostic tests

(Grouped into simple categories. Each item includes what it is and why it helps.)

A) Physical examination

1. General physical exam
   The doctor checks weight, vital signs, anemia signs (pale skin), and overall fitness for surgery or chemo. This gives a first picture of health risks and staging clues. cancer.gov

2. Abdominal exam
   Gentle pressing of the belly to feel for masses, tenderness, or fluid (ascites). This can suggest spread beyond the uterus and guide imaging. cancer.gov

3. Speculum exam
   The doctor looks at the vagina and cervix for bleeding sources, polyps, or tumors. It rules out cervical causes of bleeding and helps plan sampling. cancer.gov

4. Rectovaginal exam
   One finger in the vagina and one in the rectum to assess deep pelvic tissues and ligaments. It helps detect fixation or nodularity suggesting spread. cancer.gov

B) Manual/procedural tests

5. Endometrial biopsy (office “pipelle” sampling)
   A thin tube gently suctions a small tissue piece from the uterine lining. Pathologists can diagnose carcinosarcoma or at least detect high-grade malignancy so treatment can start. cancer.gov

6. Dilation and curettage (D&C)
   If office biopsy is not enough or not possible, a short procedure under anesthesia removes more tissue. It increases the chance of a clear diagnosis before surgery. cancer.gov

7. Hysteroscopy
   A thin camera looks inside the uterus. Doctors can see the mass directly and take targeted biopsies, which improves accuracy in complex cases. cancer.gov

8. Pelvic examination under anesthesia (at surgery)
   During the operation, the surgeon re-examines the pelvis, checks spread, and performs full staging with lymph node assessment when indicated. cancer.gov

C) Laboratory and pathological tests

9. Complete blood count (CBC)
   Checks for anemia from bleeding and for infection signs. It tells doctors how safe surgery and chemo may be. cancer.gov

10. Metabolic panel (kidney and liver function)
    Guides safe use of contrast for scans and proper dosing of chemotherapy drugs such as carboplatin. PMC

11. Pregnancy test (hCG) in premenopausal patients
    Rules out pregnancy before imaging, procedures, or anesthesia. cancer.gov

12. Tumor marker CA-125
    Not specific, but high levels can suggest extra-uterine spread and help follow response to treatment. Doctors use it along with imaging and exam. cancer.gov

13. Definitive histology on biopsy or surgery specimen
    The pathologist confirms two parts: carcinoma and sarcoma. This is the gold standard for diagnosis. ecancer

14. Immunohistochemistry (IHC) for p53, p16, and epithelial markers
    Helps classify the tumor as a high-grade endometrial carcinoma with sarcomatous differentiation and separates it from pure sarcoma. ecancer

15. MMR IHC and/or MSI testing
    Finds mismatch-repair deficiency (MMRd/MSI-H). This can open the door to immunotherapy in advanced disease. IJGC

16. HER2 testing (IHC with reflex ISH when needed)
    A subset shows HER2 amplification; identifying this may inform systemic therapy decisions in selected cases. Annals of Oncology

D) Electrodiagnostic tests

17. Electrocardiogram (ECG)
    Records heart rhythm. This is useful before anesthesia and chemotherapy, especially in older patients or those with heart risks. It helps pick safe drugs and doses. PMC

E) Imaging tests

18. Transvaginal ultrasound (TVUS)
    A small probe in the vagina uses sound waves to view the uterus. It can show a thickened lining or a mass and guides biopsy, especially in postmenopausal bleeding. cancer.gov

19. Contrast-enhanced CT scan of chest, abdomen, and pelvis
    Shows spread to lymph nodes, lungs, liver, or peritoneum. It is key for staging and planning surgery and adjuvant therapy. cancer.gov

20. Pelvic MRI
    Gives very detailed pictures of the uterus and surrounding tissues. It helps assess depth of invasion and cervical or adnexal involvement to plan the best surgery. cancer.gov

Non-pharmacological/supportive treatments

1. Oncologic surgery (TH/BSO ± omentectomy ± lymph node assessment). Purpose: remove visible tumor and stage disease. Mechanism: complete cytoreduction lowers tumor burden and informs adjuvant therapy. Standard approach is total hysterectomy with bilateral salpingo-oophorectomy; omentectomy is commonly added because microscopic omental spread can occur; nodal evaluation uses sentinel node mapping or lymphadenectomy per risk. PMC+1

2. Adjuvant external beam radiation therapy (EBRT) and/or vaginal brachytherapy (VBT). Purpose: reduce local/pelvic recurrences after surgery. Mechanism: sterilizes microscopic residual disease in pelvis/vaginal cuff. Evidence suggests improved loco-regional control; overall survival impact is mixed and case-selected. MDPI+1

3. Multidisciplinary tumor board planning. Purpose: align surgery, chemo, and radiation decisions. Mechanism: coordinated evidence-based care for a rare tumor to optimize outcomes. Grupo Geis

4. Prehabilitation (safe exercise before/around treatment). Purpose: improve fitness, reduce treatment side-effects, speed recovery. Mechanism: aerobic + resistance training supports cardiorespiratory fitness and muscle mass. Major oncology societies recommend regular exercise during active treatment when feasible. ASCOPubs+1

5. Medical nutrition therapy by an oncology dietitian. Purpose: maintain weight, muscle, and energy; manage side-effects (nausea, mucositis). Mechanism: individualized nutrition plans (adequate protein/energy; oral supplements; escalate to enteral/parenteral if needed). The ESPEN cancer-nutrition guideline provides detailed algorithms. ESPN

6. Psychosocial support & symptom management. Purpose: address anxiety, depression, sleep, and pain. Mechanism: counseling, cognitive behavioral strategies, and palliative care reduce distress and improve quality of life while disease-directed therapy proceeds. (Supported across oncologic guidelines.) ESMO

7. Lymphedema prevention/therapy (when nodes treated). Purpose: reduce limb/genital swelling after nodal surgery/radiation. Mechanism: early education, compression, and physiotherapy limit chronic lymphatic dysfunction. (Embedded within survivorship guidance.) ESMO

8. Smoking cessation & alcohol moderation. Purpose: lower complications and improve healing. Mechanism: reduces cardiopulmonary and wound risks and may lower secondary cancer risk; part of survivorship/prevention advice. Cancer.org

9. Bone health protection (for post-menopausal patients on therapy). Purpose: reduce fracture risk with calcium/vitamin D and weight-bearing exercise; DEXA scans as indicated. Mechanism: counters therapy-related bone loss. ASCOPubs

10. Structured survivorship follow-up. Purpose: detect recurrence and manage late effects. Mechanism: scheduled pelvic exams and symptom-directed imaging per endometrial cancer follow-up protocols. ESMO Open

---

Drug treatments

For UCS, carboplatin + paclitaxel is the modern standard first-line chemotherapy; it was non-inferior to paclitaxel + ifosfamide and less toxic in the large randomized NRG-GOG-0261 trial. Ifosfamide regimens are considered in select cases. Immunotherapy may be used for MMR-deficient/MSI-H disease or per endometrial carcinoma approvals (some uses are off-label specifically for UCS—marking below). ASCOPubs+1

1. Paclitaxel (IV). Class: taxane. Typical dosing in combo regimens: e.g., 175 mg/m² IV q3wk with carboplatin. Purpose: disrupts microtubules → cell death. Key risks: myelosuppression, neuropathy, hypersensitivity. (FDA label) FDA Access Data

2. Carboplatin (IV). Class: platinum. Dosing: AUC-based (e.g., AUC 5–6) q3wk with paclitaxel. Purpose: DNA cross-links → apoptosis. Risks: myelosuppression, nephro/oto less than cisplatin. (FDA labels) FDA Access Data+1

3. Ifosfamide (IV) ± paclitaxel. Class: alkylating agent. Purpose: historical standard; now often second line or for select cases because carbo-paclitaxel shows similar survival with less toxicity. Risks: myelosuppression, CNS toxicity, hemorrhagic cystitis (give mesna). (FDA labels; trial comparison) FDA Access Data+2FDA Access Data+2

4. Doxorubicin (IV). Class: anthracycline. Purpose: second-line/alternative cytotoxic option in recurrent settings (off-label for UCS). Risks: cardiomyopathy, mucositis, myelosuppression. (FDA label) FDA Access Data

5. Gemcitabine (IV). Class: antimetabolite. Purpose: salvage/cross-line chemo option (off-label for UCS). Risks: myelosuppression, pulmonary toxicity, HUS (rare). (FDA label) FDA Access Data

6. Bevacizumab (IV). Class: anti-VEGF monoclonal antibody. Purpose: combined with chemo in some recurrent endometrial cancer settings; for UCS this is off-label and considered case-by-case. Risks: hypertension, proteinuria, bleeding, GI perforation/poor wound healing. (FDA label) FDA Access Data

7. Pembrolizumab (IV). Class: PD-1 inhibitor. On-label for MSI-H/dMMR solid tumors and certain endometrial cancers; in MMRp endometrial carcinoma, pembrolizumab + lenvatinib is approved after prior platinum. Use in UCS follows the endometrial carcinoma indications; always confirm biomarker status. Risks: immune-related AEs. (FDA labels) FDA Access Data+1

8. Lenvatinib (oral) + Pembrolizumab (IV). Class: VEGFR/FGFR TKI + PD-1 inhibitor. On-label for previously treated endometrial carcinoma that is not MSI-H/dMMR; used in UCS by extrapolation to endometrial carcinoma (discuss risk/benefit). Risks: hypertension, diarrhea, fatigue; immune AEs from pembrolizumab. (FDA labels) FDA Access Data+1

9. Dostarlimab (IV). Class: PD-1 inhibitor. On-label for dMMR recurrent/advanced endometrial cancer after platinum; can be considered in UCS with confirmed dMMR. Risks: immune-related AEs. (FDA label) FDA Access Data

10. Cisplatin (IV). Class: platinum. Purpose: alternative platinum in combined regimens (off-label for UCS), sometimes in chemoradiation. Risks: nephrotoxicity, nausea, neuropathy, ototoxicity. (General endometrial cancer practice; label consulted via related platinum class where applicable.) ESMO

Why carbo-paclitaxel first? The randomized GOG-0261/NRG trial demonstrated paclitaxel–carboplatin was non-inferior to paclitaxel–ifosfamide for overall survival and progression-free survival in chemotherapy-naïve UCS, with a more favorable toxicity profile, making it the preferred standard in guidelines and practice. ASCOPubs+1

---

Supportive immune/regenerative” drugs

1. Filgrastim / G-CSF (subcutaneous/IV). Function: boosts neutrophils to lower febrile neutropenia risk during myelosuppressive chemo; mechanism: stimulates marrow granulopoiesis. Dosing varies by product; monitor ANC; bone pain is common. (FDA labels) FDA Access Data

2. Pegfilgrastim products. Function/mechanism similar to filgrastim but long-acting; single fixed dose per cycle in many regimens; same safety principles. (FDA class labeling references; representative filgrastim biosimilar label shown above.) FDA Access Data

3. Epoetin alfa / darbepoetin (ESAs). Function: treat selected chemotherapy-induced anemia to reduce transfusions; mechanism: stimulates erythropoiesis. Important: ESAs carry boxed warnings (thrombosis, potential tumor progression risk in some settings); use per strict criteria. (FDA labels) FDA Access Data+1

4. Antiemetics (e.g., 5-HT3 antagonists). Function: prevent/treat nausea from platinum/taxane chemotherapy; mechanism: serotonin-receptor blockade. Used per standard antiemetic guidelines. (General supportive-care practice referenced in endometrial cancer guidance.) ESMO

5. Growth-factor mouth care & mucositis protocols. Function: reduce mucosal injury; mechanism: oral care bundles, bland rinses; consider specific agents as indicated by center protocols. (Supportive care within guideline frameworks.) ESMO

6. Thromboprophylaxis when indicated. Function: reduce VTE risk during high-risk periods; mechanism: pharmacologic or mechanical prophylaxis per institutional guidelines. (Survivorship/oncology standards.) ESMO

---

Surgeries (what is done and why)

1. Total hysterectomy + bilateral salpingo-oophorectomy (TH/BSO). Removes uterus, cervix, tubes, and ovaries; cornerstone for localized UCS to eradicate primary tumor. PMC

2. Sentinel lymph-node mapping or lymphadenectomy. Samples nodes to stage and guide adjuvant therapy; sentinel mapping reduces morbidity vs full dissection in appropriate candidates. ICCR

3. Infracolic omentectomy and peritoneal staging. Omentum and peritoneal biopsies because microscopic omental metastases can occur in UCS. ICCR+1

4. Cytoreductive (“debulking”) surgery for advanced disease. When feasible, reduces tumor burden before systemic therapy to improve symptom control and outcomes. ESMO

5. Minimally invasive approach (laparoscopy/robotics) when safe. Offers faster recovery and fewer complications in suitable early-stage cases with equivalent oncologic outcomes. SpringerLink

---

Prevention / risk-reduction tips

1. Keep a healthy weight and active lifestyle (150–300 min/wk moderate exercise + resistance work). Cancer.org

2. Manage diabetes, blood pressure, and lipids under medical care. Cancer.org

3. Do not smoke; avoid tobacco exposure. Cancer.org

4. Limit alcohol to within national guidance (or avoid). Cancer.org

5. Report abnormal uterine bleeding immediately (earlier diagnosis improves outcomes). Society of Gynecologic Oncology

6. Discuss hormone therapy risks/benefits with clinicians if using estrogen-containing treatments. ESMO

7. Adopt a plant-forward diet rich in whole grains, legumes, fruits, and vegetables. Cancer.org

8. Adhere to follow-up schedules after treatment for early detection of recurrence. ESMO Open

9. Stay up-to-date with vaccines recommended during/after cancer treatment (per oncology clinic). ESMO

10. Participate in clinical trials when available (strongly encouraged for rare tumors like UCS). JNCCN

---

When to see a doctor urgently

See your clinician now (or go to urgent care/ER) for new post-menopausal bleeding, heavy bleeding, pelvic pain or pressure, unexplained weight loss, persistent fatigue, new leg swelling, sudden shortness of breath, chest pain, or severe uncontrolled nausea/vomiting, especially during chemo or radiation. Early evaluation can catch recurrence or complications and improve safety. Society of Gynecologic Oncology+1

---

Foods to favor and to limit

Favor: protein-rich foods (fish, eggs, tofu, legumes), whole grains, colorful vegetables, fruits, olive oil, nuts/seeds, fermented dairy (if tolerated), and adequate fluids—adjusting textures during mucositis or nausea. These support energy and muscle during therapy per ESPEN guidance. ESPN

Limit: alcohol, highly processed meats, ultra-processed snacks, very sugary drinks, excessive fried foods, and high-salt/low-nutrient items. During active treatment, avoid “neutropenic diets” by default (not proven to prevent infection); instead, practice safe food handling and individualize restrictions if neutropenic or symptomatic. PubMed

---

Dietary molecular supplements

There is no supplement proven to treat UCS. Nutrition guidelines emphasize food-first strategies and targeted supplementation only to correct deficiencies or meet needs when intake is poor. Examples your team may consider: oral nutrition supplements (energy/protein), vitamin D if low, calcium for bone health, omega-3 for weight/appetite in select patients, iron or B12/folate only if documented deficiency, and soluble-fiber products for bowel symptoms. Always coordinate with your oncology dietitian to avoid interactions. ESPN

---

FAQs

1) Is carcinosarcoma a sarcoma or a carcinoma?
Both elements exist, but behavior is mostly driven by the carcinoma part; modern practice treats it like high-grade endometrial carcinoma. MDPI

2) What is the standard first chemotherapy?
Carboplatin plus paclitaxel—supported by the NRG-GOG-0261 randomized trial showing non-inferiority versus paclitaxel-ifosfamide with less toxicity. ASCOPubs

3) Do I need radiation after surgery?
Many patients with risk factors get pelvic EBRT and/or vaginal cuff brachytherapy to reduce local recurrence; survival benefit is uncertain and individualized. MDPI

4) When are immunotherapies used?
If your tumor is dMMR/MSI-H, pembrolizumab or dostarlimab are FDA-approved for endometrial cancers; for MMRp disease that progressed after platinum, pembrolizumab + lenvatinib is approved (applies to UCS by extrapolation). Testing is essential. FDA Access Data+2FDA Access Data+2

5) What about HER2-targeted drugs?
These are used in serous endometrial carcinoma when HER2-positive; for UCS this is investigational/off-label—discuss trials. ESMO

6) How is it staged now?
By FIGO 2023 endometrial cancer staging (includes molecular features to refine risk). PMC

7) Is surgery always needed first?
When safely operable, yes; for advanced or medically inoperable cases, neoadjuvant chemotherapy and/or radiation may be used first. ESMO

8) What follow-up do I need?
Regular visits (commonly every 3–6 months initially) with history/physical; imaging is symptom-directed. ESMO Open

9) Can lifestyle help outcomes?
Yes—exercise and strong nutrition support reduce treatment side-effects and improve functional recovery; major societies endorse structured activity during treatment when safe. ASCOPubs

10) Are clinical trials important in UCS?
Very. UCS is rare; trials help access newer treatments and build evidence. JNCCN

11) Is carbo-paclitaxel given weekly or every 3 weeks?
Both schedules exist; the q3-week regimen (carboplatin AUC 5–6 + paclitaxel 175 mg/m²) is common; your oncologist adapts dosing to fitness and counts. (Regimen details align with trial/guideline practice; consult labels for drug-specific safety.) ASCOPubs

12) What labs are monitored during treatment?
CBC (for anemia/neutropenia), metabolic panel (kidney/liver), and others per drug (e.g., thyroid on lenvatinib). FDA Access Data

13) Are there diets I must follow to avoid infection?
Strict “neutropenic diets” are not recommended; instead, use safe food handling and individualized advice from your dietitian. PubMed

14) What side-effects matter most with chemo-immunotherapy?
Chemo: low blood counts, fatigue, neuropathy, nausea. Immunotherapy: immune-related effects (skin, gut, endocrine, lung). Report symptoms early. (See each FDA label for full risks.) FDA Access Data+2FDA Access Data+2

15) Does adding pembrolizumab to upfront chemo help everyone?
Not in “all-comer” high-risk endometrial cancer: an adjuvant trial (KEYNOTE-B21) did not show disease-free survival benefit across the whole group, underscoring the need to tailor by biology. Annals of Oncology

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 10, 2025.